<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19888">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732211</url>
  </required_header>
  <id_info>
    <org_study_id>A6261009</org_study_id>
    <nct_id>NCT01732211</nct_id>
  </id_info>
  <brief_title>A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, 20 Week, Safety, Tolerability, and Efficacy Study of PD 0360324 in Adult Subjects With Chronic Pulmonary Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in
      subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care
      therapies.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline in % predicted Forced Vital Capacity (FVC) compared to placebo at Week 16.</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary efficacy endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in chest X ray global assessment score (5 point Likert Scale)</measure>
    <time_frame>Baseline to 20 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FVC (absolute and % predicted) compared to placebo at other time points post baseline except Week 16.</measure>
    <time_frame>Baseline to 20 weeks (except Week 16)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated treatment effect over placebo in FVC averaged over 16 weeks.</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in other spirometric parameters at all timepoints post baseline: Forced Expiratory Volume in 1 Second (FEV1), % predicted FEV1, ratio of FEV1/FVC.</measure>
    <time_frame>all timepoints post baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary Efficacy Endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pulmonary Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>PD 0360324</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD 0360324</intervention_name>
    <description>100 mg Q2W or 150 mg Q2W  via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;</description>
    <arm_group_label>PD 0360324</arm_group_label>
    <other_name>Investigational Study Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline for injection</intervention_name>
    <description>normal saline Q2W via intravenous infusion for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of biopsy-proved chronic pulmonary sarcoidosis either Stage 2 or Stage 3
             for at least 1 year;

          -  Forced Vital Capacity (FVC) lung assessment of &gt;40% and &lt; or = to 80% predicted
             normal values at screening;

          -  age 21-75 years of age;

          -  treatment with a stable (longer than 4 weeks) regimen of corticosteroids (between 10
             and 30 mg of prednisone) for at least 3 months prior to Screening; (other
             anti-inflammatory drugs may be permitted as defined by the study protocol)

        Exclusion Criteria:

          -  History of any other pulmonary (lung) disease than sarcoidosis (ex, asthma requiring
             maintenance treatment, chronic obstructive pulmonary disease (COPD));

          -  Pulmonary hypertension, significant lung fibrosis, any chronic infection (eg, TB,
             HIV);

          -  treatment with other biologic anti-inflammatory/immuno-modulatory drugs;

          -  active smokers;

          -  class 3 or 4 congestive heart failure;

          -  cancer, or history of cancer within past 5 years;

          -  history of ischemic heart disease, heart attack, stroke, any heart muscle disease;

          -  liver disease;

          -  history of alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6261009&amp;StudyName=A%20Phase%202%2C%20Safety%2C%20Tolerability%2C%20and%20Efficacy%20Study%20of%20PD%200360324%20in%20Chronic%20Pulmonary%20Sarcoidosis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2</keyword>
  <keyword>Randomized</keyword>
  <keyword>Double Blind</keyword>
  <keyword>Placebo Controlled</keyword>
  <keyword>Parallel</keyword>
  <keyword>20 Week Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>and Efficacy Study</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
